Efficacy of TP-271 Formulation in the Mouse Lung Infection Model with Streptococcus Pneumoniae

Project Details

StatusFinished
Effective start/end date4/12/12 → 3/12/13

Funding

  • Tetraphase Pharmaceuticals Inc.: $27,014.58
View all
View less

Keywords

  • Biotechnology & Drug Development, Infectious Diseases